Race/Ethnicity
AASLD 2013: Black Hepatitis C Patients Do Well on Sofosbuvir Oral Regimens
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 21 November 2013 00:00
- Written by Liz Highleyman
Interferon-free treatment using a single daily combination pill containing sofosbuvir plus ledipasvir demonstrated potent anti-HCV activity and was generally well-tolerated in a primarily African-American inner city population with genotype 1a hepatitis C, researchers reported at the recent AASLD Liver Meeting in Washington, DC. Adding a third drug resulted in high early post-treatment response rates with shorter treatment.
AASLD 2013: Tenofovir Alafenamide Shows Similar Anti-HBV Activity with Less Kidney Toxicity
- Details
- Category: Experimental HBV Drugs
- Published on Thursday, 21 November 2013 00:00
- Written by Liz Highleyman
A new formulation of tenofovir that can be taken at lower doses demonstrated potent activity against hepatitis B virus (HBV) similar to that of the existing formulation in a 28-day study, but with less effect on kidney function, researchers reported at the 64thAASLD Liver Meeting this month in Washington, DC.
AASLD 2012: Is a Simple Sofosbuvir + Ribavirin Regimen Suitable for Hard-to-treat HCV Patients?
- Details
- Category: HCV Treatment
- Published on Wednesday, 05 December 2012 00:00
- Written by Liz Highleyman
An all-oral dual regimen of sofosbuvir plus full-dose ribavirin was well-tolerated and produced 4-week post-treatment sustained response in approximately three-quarters of previously untreated genotype 1 chronic hepatitis C patients in an inner-city pilot study, researchers reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) last month in Boston. Reducing the ribavirin dose, however, lowered response rates.
More Articles...
- National Medical Association Releases Report on Hepatitis C Among African Americans
- Racial Differences in Eligibility for Hepatitis C Treatment
- African Americans with Hepatitis C Have Worse Outcomes than White Patients after Liver Transplantation
- African Americans with Genotype 1 Hepatitis C Less Likely to Have Steatosis
Web Design and Development by